The underlying therapeutic effect of miR-29b against AD is based on the downregulation of NAV3 (neuron navigator), β-site amyloid precursor protein cleaving enzyme 1 (BACE1) and Bcl-2 interacting mediator of cell death (BIM) expression. This evidence concerns the gene BACE1 and Alzheimer disease.